The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
We have probably reached the point where it is too late to commence P2 trials during Q2, 2024. The poster presentation at ATS 2024 was sadly just that. I had hoped that it would be quickly followed by an RNS statement concerning the proposed trials.
Like some other investors, I have all but given up on the CEO and his executives. They evidently lack the ability and wherewithal to take SNG001 forward to further trialling. Nothing of any material benefit to investors has happened as the result of their assumed activity over the last 27 months.
Our best hope appears to lie with TFG Holdings, and their next steps. Should they “persuade” the company to place their valuable IP in the hands of a major biopharmaceutical entity to everyone’s benefit, we may have an opportunity of recouping some of our losses? Perhaps I am being naive in thinking that anything of this nature could happen?
As always, I shall, as ever, be happy to learn that my pessimism regarding the company’s leadership was incorrect, and unfounded. A long running saga, with nothing whatsoever achieved, and very little dialogue with investors has brought this about.
GLALTIs.
All Synairgen investors will be relieved to learn when the results of a significant study will contribute to the patient protocols for the company’s forthcoming P2 trials. I look forward to that announcement, particularly if it reinvigorates the company, and its share price in particular.
The statement “ Synargen have been doing more than some would summarise ” is a curious comment, especially coming from someone with more detailed knowledge about the company than most investors.
We have known about Synairgen’s role in the Universal study since its inception.
“Synairgen is providing viral testing equipment and nursing staff at the Southampton clinical trial site.”
Pedro Rodriguez, whose name is included on the publication, is a Clinical Research Nurse Manager and Junior Project Manager at Synairgen. It seems more than likely that he has been seconded by Synairgen to lend his expertise to the study, as stated above.
My optimism for a favourable outcome to my investment remains. It is such a shame that some investors, who still maintain a high degree of confidence in the company’s leadership, choose to constantly contradict others, who are more reserved in their opinion.
The only important factor is that Synairgen progresses towards a successful endpoint to the benefit of its investors.
GLALTIs.
There is nothing bewildering about any of my statements, nor those of other valued contributors. Unfortunately, the expert on diversionary tactics invariably attempts to make light of our opinions because they don’t tally with his worldview.
This is a discussion board where individuals are free to offer their opinions. Many choose to quote supportive evidence through unconnected scientific papers to validate their thoughts. Not one of these has added a cent to the Synairgen share price, as they are not linked directly to our investment case.
I hope that our self-proclaimed expert, who attempts to denigrate the views of others through attempted witticisms is correct on this occasion.
Investors are in serious need of a meaningful update from Synairgen. The CEO and his leadership team have produced nothing of value in 27 months. This is evidenced by the continuous decline in the share price to the current level!
GLALTIs.
At 07:00 I was anticipating an RNS linking today’s ATS 2024 poster presentation to the trial protocols for the expected company P2 trials - scheduled to start before the end of June 2024.
Since May 23, 2023, Synairgen have issued 8 RNS statements. The last of these was on November 15, 2023. They include announcing an annual report and AGM date on May 23, 2023. This year’s equivalent statement is surely due this week or next?
Perhaps when it is released, it will enlighten investors about the expected P2 trials? There really has been nothing of substance in the last year. The eight RNSs are common or garden, and include two statements of Grant of Options statements and two announcing appointments to the Senior Leadership Team.
It really is concerning that we are approaching the end of H1 2024, and there has been little announced in a whole year apart from two recent poster presentations in which nothing substantially new his being offered? Neither of these has merited an RNS.
GLALTIs.
Professional.
I have no idea how this investment will proceed? However, given the right news ( hopefully during Q2?), I am anticipating an initial rise well in excess of £0.20. It all hinges on what Synairgen have achieved during the last 7+ months?
I agree with JD in that I couldn’t discern anything new in the ATS abstract. As I am not qualified to offer an opinion, I requested other more knowledgeable investors for their views earlier today. As I read it, the general consensus is positive, and I look forward to receiving further clarification from Synairgen when they are ready to enlighten us?
As stated, we will be on our way, given the right news, but for the moment I am remaining guardedly optimistic.
GLALTIs.
Thank you for posting the link Owl11.
"Analysis of Baseline Factors Associated With Poor Clinical Outcome in a Phase 3 Trial in Patients Hospitalized Due to COVID-19."
The lead author of the presentation is Dr. V Tear, who is a senior scientist at Synairgen and an experienced participant at Synairgen poster sessions. I note that she attended the UKHSA/SNG poster presentation at the Microbiology. Society Annual Conference in Edinburgh, and was a co-presenter, with Prof Tom Wilkinson, of the first Host Directed podcast. She is likely to be the lead presenter, being the contact person regarding the abstract. Her obvious competence adds to my confidence that the message will get through to interested (hopefully significantly so) attendees at the ATS 2024 conference.
I have read Dr Tear's abstract, but am not qualified to comment on its significance. Is this presentation leading to what we are all expecting, namely Synairgen's patient protocols for the expected forthcoming P2 trials? I would appreciate a brief comment from our more knowledgable contributors, who frequently offer scientific content to this forum, should you have the time, that is. Should it be the first step towards the protocols for the aforementioned trials, it will come as a welcome relief!
Thank you for your response wpa5. As always, your opinion is appreciated. I am as yet uncertain whether I would remain invested beyond a break even point, should that be achieved? My reasoning is simple. I did just that between December 2021 - February 2022, when I could, and should have sold my Synairgen stock for a profit. I retain a high level of confidence in SNG001, but unfortunately not in Synairgen's CEO and Board. Wheres I own my current paper losses, I doubt whether I would now trust the company beyond a break-even/return to profit level. It is still early days though. Nothing new has been shared with investors for well over two years. A significant piece of information from the company could well change my opinion.
GLALTIs.
Fnv.
Should the route towards approval and commercialisation result in a profit ( or even a break-even point) from the current position, I will be happy. I believe that I am right in thinking that all investors, like myself, who were over invested prior to the Sprinter trial outcome, and sustained losses as a result, will have a similar point of view.
Agreed, more deliberate manipulation to satisfy the ongoing greed of a small number of individuals.
They have lost sight of the importance of the company’s IP. This could eventually be of enormous benefit to a large number of seriously ill people.
Instead of promoting and developing the company, these sharks are continuing to use it purely to increase their wealth. What sad pathetic individuals they all are!
It is not a case of loyalty. That is something that is earned, and the CEO and Board have done little or nothing to deserve any loyalty from shareholders,
It is a case of maintaining a belief in the company’s core product, and its future as an important broad- spectrum antiviral treatment. A worldwide need for it exists. Should the company’s current strategy/negotiations - whatever is actually going on during the current level by term silence? - result in a good outcome for investors, I will be well satisfied.
Personally, I don’t give two hoots about the CEO and his acolytes, as they have treated shareholders shabbily for far too long. Should their actions, however inappropriate, result in a good profit, that is all that matters to me.
GLALTIs.
I noted that the BRH share price was down by > 40% this morning following an RNS about the revaluation of its assets. It would appear that TB commands the same level of respect from BRH investors as is the case here. Leopards and spots spring to mind.
I remain optimistic of an eventual decent return here, although I don't see the point of the IB LinkedIn messages, which attract practically no attention. How long will it take before we receive detailed notification of recent sales, and growth figures?
GLALTIs.
Our last significant update in September 2023 included the following:
"Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral "shedders", a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024."
It is not unreasonable to deduce that, seven and a half months later, there ought to have been a further update on the progress of the preparatory work, and the likely trial launch dates by now? As was the case during Winter 2022-2023, when we were anticipating something similar, a trial announcement is looking less likely with each passing day.
Is it possible that there may be a plan B afoot, as some investors here have suggested? My patience with the vague statements, obfuscation, and sheer arrogance from the CEO and his BOD over more than two years has long ran out. I am seriously doubting their competence in taking our treatment forward. Those who maintain that there is still six weeks left in H1 2024 have a point. However, should it always be the case of a last minute update from Synairgen, with a long period of silence beforehand? Good companies are not usually led in such a shabby way, with total disregard for LTIs in particular!
Still no white smoke, but the reasonable forecast dates on fidelity.co.uk, suggest that we might be receiving an update later this month? Perhaps this may be announced on the company’s website, hence my daily check for information.
https://www.fidelity.co.uk/factsheet-data/factsheet/GB00B0381Z20-synairgen/news-key-dates-and-documents
It speaks volumes that there isn’t even perfunctory information concerning expected updates in available to investors.
To your credit Doc83, you have already done just that during the last two AGMs, together with a number of well-respected investors, who nowadays occasionally comment on this forum.
Synairgen will move their strategy forward, when it suits them. Past precedent shows that they won’t respond in any shape or form to investors’ comments or requests.
In any case, surely we will have some information regarding the launch of the P2 trials before the AGM date is announced? Otherwise, the implication may well be yet further delay?
Correction: Feb 2022
Hatter01.
I agree that an 8p valuation is meaningless to LTIs, whose shareholding depreciated by over 90% instantly, and as yet irredeemably in Feb 2024.
I also concur that the dearth of any measurable progress since then, borne out by the steady fall in share price since then is concerning.
That being said, a strategy has been in place for well over seven months. Coupled with this, diligent researchers on this forum have copiously pointed out the world wide need for a broad spectrum antiviral product like Synairgen.
However, the company really do need to begin the anticipated P2 trialling soon, if they are to maintain any credibility. They may well embark on an alternative path? Any positive development from here onwards would be welcome.
Most individuals expressing concern are frustrated investors caught up in the unfortunate Sprinter outcome, who have kept faith with their investment. As things have turned out, it might have been wiser to move on in mid 2022, when the share price showed something of a resurgence to 30p+? That opportunity has long gone, and soon we will know whether our faith in holding onto our investment will be repaid with positive news from the company? One way or another, it won’t be too long now!
GLALTIs.
Oddly, I have taken some encouragement from reading some recent comments here. Why have DB issued this assessment after 7 months?
Presumably, the analyst has worked for DB since the Numis acquisition? It would seem reasonable for him to have reissued an updated Synairgen broker’s note before now?
Has the analyst been prompted recently by the company, or by TFG perhaps, to begin following Synairgen again and to issue an initial assessment to lay down a marker?
This supposes that there are going to be developments ahead, and with them an increase in share price. It has happened with Synairgen before. In early January 2020, the share price was around the current level. Successive developments brought with them significant share price increases culminating in the post P2 moonshot, when the share price rose by 3OX the January 2020 value.
Given a successful outcome to the strategy from September 2023, we could well see success of this kind being repeated? Having brokers on board to monitor the progress and issue advice to investors is an essential part of this process.
I remain somewhat sceptical until we receive news from Synairgen on their strategy's progress. However, today’s note could well be the start of something provided it is followed by positive news on the P2 trials? Until that happens, there is little to discuss. I am guardedly optimistic, and shall continue to check each morning for that elusive RNS.
All IMHO. GLALTIs.
MrCosts.
Explained by Doc83 below. No real substance to it.
There is no 10% drop either. One small sell, amidst a number of small buys at around the current share price.
The next substantial RNS should be instructive? I have thought the same in the past, so I shall continue to wait, and see what eventually happens?
I will take 8p/Hold from DB rather than Ghia’s recent assessment. There is no update to underpin it, although I agree that there is probably a good reason for its introduction.
I shan’t mention trolls on this forum again, but will continue to filter their messages as before. I now believe that most contributors’ assessment of Sakura7 is correct. S/he initiated the most ludicrous conversation I have seen on a share discussion board.
I hope that today’s DB rating, will soon be followed by a significant update from Synairgen to upwardly reset the company’s ludicrous valuation, currently based on our cash reserve?
GLALTIs.
Manifesto.
Under AIM rules, 75% of all shareholders need to be in favour before delisting can happen. For obvious reasons, that scenario is not an option for the CEO and BOD to consider.
Even if the vast majority of private investors were favourably inclined towards delisting , TFG Holdings with their 28.3% shareholding, are in effective control of the process.
Fruitsnveg.
“I'll do me and you do you - none of us need to be told.”
Fine! That implies that we have more of your immature response to other contributors to look forward to. I am grateful that you at least indulged me with a sensible reply.
With regards to your labelling me and others as having nefarious reasons for contributing here, that is beyond a joke.
You recently stated that our uncommunicative CEO was well respected by BP companies. Do you have any evidence to validate that statement? I won’t counter by suggesting that you may have a hidden agenda in offering this information? However, it wouldn’t be unreasonable to make that deduction.